Phase I study of erlotinib (E) for solid tumors in patients with hepatic or renal dysfunction (HD or RD): CALGB 60101
A. A. Miller(Leukemia Research Foundation), Mark J. Ratain(University of Chicago), Miguel A. Villalona‐Calero(University of California, Irvine), J. L. Marshall(Leukemia Research Foundation), Kouros Owzar(Duke University), Donna Hollis(University of North Carolina at Chapel Hill), Lionel D. Lewis(Dartmouth College), Hedy L. Kindler(University of Chicago), Martin J. Edelman(Fox Chase Cancer Center), D. J. Murry(Leukemia Research Foundation)
Cited by 2
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k